Ann: First-in-human study update - First patient enrolled, page-181

Hi all,

As some of you may notice, Imagion’s CEO Bob Proulx was featured in a new article published in Drug Discovery & Development commenting on the innovative therapeutic approaches being developed by Global Cancer Technology. 

We have previously noted in this forum that Imagion has undertaken some early-stage collaboration with GCT on the nanoscintillator technology. Imagion is using the relationship to evaluate the opportunity to use its expertise in nanoparticles to help further develop the technology.

We’re happy to see GCT getting recognition for the very exciting technologies they are developing.

You can read the full article here: https://bit.ly/3w5VKCj